Aspirin prevents Preeclampsia and related Morbidity and Mortality: USPSTF
US Preventive Services Task Force updated its 2014 recommendation as published in the JAMA and commissioned a systematic review to evaluate the effectiveness of low-dose aspirin use to prevent preeclampsia.
Pregnant persons at high risk for preeclampsia who have no prior adverse effects with or contraindications to low-dose aspirin were selected.
The USPSTF concludes with moderate certainty that there is a substantial net benefit of daily low-dose aspirin use to reduce the risk for preeclampsia, preterm birth, small for gestational age/intrauterine growth restriction, and perinatal mortality in pregnant persons at high risk for preeclampsia.
Below is the summary of the recommendations:
· Preeclampsia is one of the most serious health problems that affect pregnant persons.
· It is a multisystem inflammatory syndrome that is often progressive but has an unclear aetiology.
· Worldwide, preeclampsia is the second most common cause of maternal morbidity and mortality.
· It is a complication in approximately 4% of pregnancies in the US and contributes to both maternal and infant morbidity and mortality.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.